Intratumoral heterogeneity in cancer progression and response to immunotherapy
Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …
[HTML][HTML] EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
M Weller, M van den Bent, M Preusser… - Nature reviews Clinical …, 2021 - nature.com
In response to major changes in diagnostic algorithms and the publication of mature results
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …
Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …
[HTML][HTML] High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
Transcriptome analysis reveals tumor microenvironment changes in glioblastoma
Y Hoogstrate, K Draaisma, SA Ghisai, L van Hijfte… - Cancer Cell, 2023 - cell.com
A better understanding of transcriptional evolution of IDH-wild-type glioblastoma may be
crucial for treatment optimization. Here, we perform RNA sequencing (RNA-seq)(n= 322 test …
crucial for treatment optimization. Here, we perform RNA sequencing (RNA-seq)(n= 322 test …
Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression
Glioblastoma (GBM), a highly lethal brain cancer, is notorious for immunosuppression, but
the mechanisms remain unclear. Here, we documented a temporospatial patterning of tumor …
the mechanisms remain unclear. Here, we documented a temporospatial patterning of tumor …
FDA approval summary: pembrolizumab for the treatment of tumor mutational burden–high solid tumors
The FDA approved pembrolizumab on June 16, 2020, for the treatment of adult and pediatric
patients with unresectable or metastatic tumor mutational burden–high [TMB-H;≥ 10 …
patients with unresectable or metastatic tumor mutational burden–high [TMB-H;≥ 10 …
[HTML][HTML] A vaccine targeting mutant IDH1 in newly diagnosed glioma
Abstract Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of
diffuse glioma,–. The most common IDH1 mutation in gliomas affects codon 132 and …
diffuse glioma,–. The most common IDH1 mutation in gliomas affects codon 132 and …
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing
great interest in the neuro-oncology community. While several reports show that subsets of …
great interest in the neuro-oncology community. While several reports show that subsets of …
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …
outcome with regard to multiple tumour types. However, most patients still do not benefit …